Financial News
DateTitlemore >
Sep. 4, 2008Amgen and Wyeth Statement on the FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Aug. 22, 2008FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP
Jul. 31, 2008Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc.
Jul. 30, 2008Amgen Issues Statement in Response to Revised ESA Labeling Received from the FDA Today
Jul. 28, 2008Amgen's Second Quarter 2008 Adjusted Earnings Per Share Increased 2 Percent to $1.14
Jul. 25, 2008Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
Related Links Stock Quote


AMGN: NASDAQ
$60.16

 (Minimum 20 minute delay)